His academic research has broadened the understanding of glucagon physiology while championing the discovery of single molecule mixed agonists for the treatment of diabetes and obesity. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization, an approach he has termed chemical-biotechnology. DiMarchi also significantly contributed to the commercial development of Humulin®, Humatrope®, and Evista®. He is widely recognized for discovery and development of rDNA-derived Humalog® (LisPro-human insulin), rGlucagon®, and Forteo®. DiMarchi is a vice president at Novo Nordisk Research Laboratories and a retired group vice president at Eli Lilly and Company, where for more than two decades he provided leadership in biotechnology, endocrine research, and product development. He is currently chairman of the Peptide Therapeutics Foundation and an external board member at Assembly Biosciences.ĭr. He has served as a scientific advisor to multiple pharmaceutical companies and venture funds. He is a co-founder of Ambrx, Inc., Marcadia Biotech, Assembly Biosciences, Calibrium, and MB2 Biotech. He is a Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University. DiMarchi’s contribution in chemistry and related sciences consists of nearly four decades of work in academics, the pharmaceutical industry, and biotechnology.
Postdoctoral Fellowship at Rockefeller University, 1981.
0 kommentar(er)
